Related Experiment Videos
Citalopram to treat depression in pediatric oncology
Margaret DeJong1, Eric Fombonne
1South West London and St. George's Mental Health NHS Trust and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom, and McGill University, Montreal, Canada. margaret.dejong@rmh.nhs.uk
Abstract:
We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective reuptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Electroconvulsive Therapy
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Psychosis: Goals of Pharmacotherapy